Across TCGA pan-cancer cohorts, IL17D Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IL17D data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IL17D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL17D expression acts as an unfavorable survival marker.
UCEC are the cancer types where IL17D Mutation most reproducibly stratifies survival.